CMAJ
July 9, 2013
vol. 185
no. 10
- Review
Preventing cognitive decline in healthy older adults
- Raza Naqvi, MD⇑,
- Dan Liberman, MD,
- Jarred Rosenberg, MD,
- Jillian Alston, MD,
- Sharon Straus, MD MSc
- From the Divisions of Geriatric Medicine (Naqvi, Liberman, Rosenberg, Straus) and General Internal Medicine (Alston), Department of Medicine, University of Toronto, Toronto, Ont.
- Correspondence to: Raza Naqvi, raza.naqvi{at}utoronto.ca
Given the increase in the aging population,
the prevention of cognitive decline in healthy older adults deserves
close attention.
Mild cognitive impairment affects 10%–25% of people
over the age of 70 years.1
Mild cognitive impairment involves cognitive decline beyond that
normally expected in a person of the same age with preservation
of function. Dementia is defined as cognitive decline
in one of several cognitive domains, along with difficulty in functional
abilities. The annual rate of conversion from mild
cognitive impairment to dementia is about 10%.2 Given this rate, in combination with the aging population, it is estimated that the prevalence of dementia will double to
more than 1 million Canadians over the next 25 years.3
A summary of our search strategy is outlined in Box 1.
Our search included randomized controlled trials (RCTs) involving
participants with normal cognition. We also searched for
RCTs involving participants with mild cognitive
impairment. Given the substantial differences between people with normal
cognition
and those with mild cognitive impairment, this review
focuses on people with normal baseline cognition, which constitutes
most of the older population.
Box 1:
Evidence for this review
-
We searched MEDLINE, Embase, CINAHL (Cumulative Index to Nursing and Allied Health Literature) and Cochrane Central Register of Controlled Trials from the date of database onset until Oct. 31, 2011, using a list of search terms that included “cognitive decline,” “dementia” and “mild cognitive impairment” (for the full list of terms, see Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.121448/-/DC1). Our inclusion criteria were randomized controlled trials of pharmacologic or nonpharmacologic interventions in patients aged 65 years and older with normal baseline cognition or mild cognitive impairment. We included studies that investigated any form of cognitive decline, including the development of mild cognitive impairment, progression to dementia or worsening cognitive function on cognitive testing.
-
The initial search found 5205 articles, and multiple levels of screening yielded 32 articles for the review (see Appendix 1 for screening algorithms). We assessed study quality using the criteria developed by the Cochrane Effective Practice and Organisation of Care group (http://epoc.cochrane.org/epoc-methods), which assesses risk of bias. Whereas the overall quality of the literature was moderate, most studies had substantial limitations in methodology or data analysis (see Appendix 2, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.121448/-/DC1).
The prevention of cognitive decline is an important concern for many older adults.4
There are many organizations and industries that target the public with
claims that use of their products will prevent cognitive
decline. These products range from physical and
cognitive programs to prescription and nonprescription medications. The
evidence
to support use of these products is sparse, and both
the public and clinicians find it challenging to identify which
strategies
might be effective in preventing cognitive decline.
Often, the data regarding these interventions are conflicting, and the
studies are of poor quality. The objective of our
review is to clarify the evidence with a comprehensive review of
high-quality
published studies that investigated strategies to
prevent cognitive decline in healthy older adults, for the purpose of
providing
guidance to older adults and their clinicians. We
defined cognitive decline as any decline found by neuropsychiatric
testing
or increase in the incidence of mild cognitive
impairment or dementia.
What pharmacologic interventions might be effective in preventing cognitive decline in older adults?
There is no strong evidence for the use of any pharmacologic interventions to prevent cognitive decline in healthy older adults
(Table 1).5–36
However, there is some evidence of harm with certain pharmacologic
therapies, including estrogen therapies and anti-inflammatory
drugs.8–11,28
View this table:
Table 1:
Summary of results from randomized controlled trials that investigated the prevention of cognitive decline in healthy older
adults
Cholinesterase inhibitors and N-methyl-d-aspartate glutamate receptor antagonists
Cholinesterase inhibitors and N-methyl-d-aspartate
(NMDA) receptor antagonists are approved for use in patients with
dementia in an attempt to slow down cognitive
and functional decline. Three RCTs investigated
the effects of cholinesterase inhibitors or NMDA receptor antagonists
for
preventing cognitive decline in cognitively
normal older adults.5–7
Cholinesterase inhibitors prevent the breakdown of acetylcholine, a
chemical involved in neurotransmission, by inhibiting
acetylcholinesterase. The NMDA receptor
antagonists are thought to selectively block the excitotoxic effects
associated with
abnormal transmission of glutamate. A total of
89 patients were included in these trials, and follow-up ranged from 3
to 15
months. One study investigating donepezil5 included 20 patients and showed improvement in immediate (p = 0.012) and delayed (p = 0.006) semantic recall at 10-week follow-up, with no changes in immediate and delayed superficial recall. The 2 other RCTs
investigated donepezil and memantine, and showed no evidence of improved memory or cognition.6,7
Hormonal therapies
Estrogen
Seven RCTs investigated the effects of estrogen and its derivatives, including 4 trials coordinated by the Women’s Health
Initiative Memory Study (WHIMS) group.8–14 A total of 10 792 patients were involved in these RCTs, 10 426 of whom were involved in the WHIMS trials. Follow-up of patients
ranged from 4 to 5 years for the WHIMS trials8–11 and from 2 weeks to 1 year for the other studies.12–14 These studies indicated a relative decline in cognitive function and an increase in incident dementia in patients in the
treatment arms with hormonal therapy (hazard ratio 1.8, 95% confidence interval [CI] 1.2 to 2.6).
Testosterone
Three RCTs studied testosterone use in 144 men, with study follow-up ranging from 3 months to 3 years.15–17 The results were conflicting, with the shortest study of 3 months showing some possible improvement in spatial (p = 0.01) and verbal (p = 0.05) memory.15 Another study indicated worsening in short-term memory (p < 0.05, effect size 0.59) with testosterone treatment at 9 months,16 and the third study showed no significant change in memory-related outcomes over 3 years.17
Dehydroepiandrosterone
Dehydroepiandrosterone (DHEA) is a natural hormone that can be synthetically produced and is frequently marketed as an agent
that can prevent cognitive decline.37 Three RCTs18–20 investigated the use of DHEA in a total of 317 patients. Follow-up was from 6 weeks to 1 year. None of the 3 studies showed
a statistically significant improvement in cognitive function with the use of DHEA supplements.
Ginkgo
Ginkgo is a popular herbal supplement available worldwide that is thought to have anti-oxidant effects and to possibly affect neurotransmitters in a
manner that is not well characterized.38 Two RCTs have investigated the prevention of cognitive decline with ginkgo.21,22 One that followed 230 cognitively healthy older adults for 6 weeks did not show a significant difference in any cognitive
outcome measured.21 Another RCT studied 118 patients over 42 months and also found no significant change in cognitive decline between the gingko
and placebo groups.22
Vitamins and fatty acids
Randomized controlled trials have assessed the use of various vitamins and fatty acids for the prevention of cognitive decline.
Vitamin B6 (n = 76, study duration 12 wk23), vitamin E (n = 6377, study duration nearly 10 yr24), folic acid (n = 24, study duration 4 wk25) and the omega-3 fatty acid EPA–DHA (eicosapentaenoic acid–docosahexaenoic acid; n = 302, study duration 6 mo26) have all been studied, and none showed evidence of preventing cognitive decline.
Miscellaneous pharmacologic interventions
Four RCTs investigated other pharmacologic interventions to determine if they prevent cognitive decline in healthy older adults.27–30 One study examined the effects of candesartan over 4 years among nearly 5000 patients, but no significant change in cognition
was noted with its use.27
A second study conducted over 3 years investigated the use of naproxen
and celecoxib among 2500 patients and found a marginal
decline in memory with use of the medications;
global summary scores were 0.05 standard deviations lower (p = 0.02) in the treatment arm.28 A 4-week study of a placebo versus no pill in 40 older adults reported an improvement in delayed recall with placebo (p = 0.035), but review of the CI for the point estimate showed that the result was not statistically significant (CI −0.3 to
1.3).29 Another study investigated AIT-082 (n = 9, follow-up 5 wk), an oral nerve growth factor, which found no significant improvement in memory with intervention.30
Do any nonpharmacologic interventions prevent cognitive decline?
One RCT investigating resistance training in healthy older adults showed improvement in cognitive outcomes.31 There is consistent evidence that cognitive training using formal programs is effective at preventing cognitive decline based
on 3 RCTs (Table 1).34–36
Physical exercise
Three RCTs have investigated the role of physical exercise in preventing cognitive decline. Cassilhas and colleagues31
investigated resistance-training protocols of moderate and high
intensity compared with a placebo stretching group in a study
involving 62 men over 6 months. The
resistance-training protocols consisted of 3 one-hour sessions per week
beginning with
a 10-minute warm-up and then using varying
resistance loads under professional supervision. The authors found a
statistically
significant improvement in some, but not all,
tests of short-term and long-term episodic memory.31 The authors did not report an overall change in cognition.
A second RCT compared resistance-and
balance-training exercises with a flexibility and relaxation program, as
well as a no-exercise
control. The study, which included 152 healthy
older adults who were followed for 1 year, showed no significant
improvement
in visual, verbal or working memory with the
intervention compared with the flexibility and relaxation program, or
the no-exercise
control.32
Baker and colleagues33
completed a 6-month study with 28 participants comparing aerobic
exercise (participants used treadmills, stationary bicycles
or elliptical trainers to reach 75%–85% of their
heart rate reserve) to stretching (participants carried out stretching
and
balancing exercises while maintaining their
heart rates at or below 50% of their reserve). This study found benefits
in executive
function (p = 0.04) but not in memory in the aerobic exercise group.33
Cognitive training
Three RCTs explored the role of various forms of cognitive training, which can also be referred to as mental exercise, to
prevent cognitive decline in healthy older adults. Willis and colleagues34
investigated the role of cognitive training in reasoning, speed or
memory in 2802 healthy older adults. All 3 groups showed
significant improvements in memory over the
5-year follow-up period, with a relatively greater effect size in the
memory-trained
group compared with the reasoning- or
speed-training groups (effect size 0.23 v. 0.05). The effect size was
defined as the
difference in improvement from baseline to year 5
between the training and control groups divided by intrasubject
standard
deviation of the Blom-transformed composite
score.
Smith and colleagues35
compared a computerized cognitive training program based on brain
plasticity with a general cognitive stimulation program
over 8 weeks in 487 older adults. There was a
significant improvement in auditory memory and attention in the
treatment group
compared with the control group (p = 0.02) with an improvement of 2.1 points (3.9 points, 95% CI 2.7 to 5.1, v. 1.8 points, 95% CI 0.6 to 3.0) on a 100-point
scale;35 however, the overlap in CIs between the treatment and control groups indicates that the significance of the difference is
unclear.
Berry and colleagues36
assessed the impact of 10 hours of computerized visual demonstration
training compared with no training in a study of 32
people over 4 weeks. They found statistically
significant improvement in performance after 4 weeks in the intervention
group
compared with the control group (p < 0.05, effect size 0.81), not only in the trained perceptual task but also in untrained working memory tasks.36
Modification of vascular risk factors
We found no RCTs that investigated the
modification of vascular risk factors and their impact on the
prevention of cognitive
decline in healthy older adults. As mentioned,
one RCT did look specifically at the use of candesartan and found no
significant
difference in cognitive outcomes over 4 years.27
However, we found no RCTs that investigated overall blood pressure
control, weight reduction, smoking cessation or other
interventions related to reduction of vascular
risk factors that may be hypothesized to reduce cognitive decline.
Limitations and future directions
This review was limited to
English-language studies. We did not include studies involving patients
with mild cognitive impairment
because this was outside the scope of our review.
As with any review, we were limited by the quality of studies available
in the literature. Notably, most studies had
relatively short follow-up periods for interventions aimed at preventing
cognitive
decline. Furthermore, several studies selectively
reported data and most used numerous end-points, which made the
significance
of positive results questionable in the setting of
many non-significant changes within the same study. The highly variable
outcome measures in terms of various tests used to
investigate memory outcomes makes it difficult to compare results across
studies. One of the most substantial limitations in
this review is that the changes observed do not appear to be clinically
significant.
A recent Cochrane Review examined cognitively stimulating activities and their role in preventing cognitive decline in older
adults with normal cognition or mild cognitive impairment.39 The study concluded that studies with no-activity controls showed significant improvement, whereas studies with active controls
(compared with another intervention) did not reach statistical significance.39 Our review did not include studies with minimal cognitive impairment; however, one of the 3 studies that investigated cognitive
training35 did use an active control and found a relative benefit to a cognition-based training program.
This review provides some evidence to help clinicians and their patients address what strategies might prevent cognitive decline
(Box 2).
There is a lack of RCT data on other commonly proposed “anti-aging”
strategies, including drinking wine and dietary restrictions,
and thus we cannot comment on the potential benefit
or harm of these strategies. Future studies should address the impact
of cognitive training on the prevention of
cognitive decline, and we encourage researchers to consider easily
accessible tools
such as crosswords puzzles and sudoku that have not
been rigorously studied. The studies in this review that assessed
cognitive
exercises used exercises that were both labour-and
resource-intensive, and thus may not be applicable to most patients.
Box 2:
Applying the results of this review to clinical practice
-
When patients are seen in the primary care clinic and are interested in knowing whether they can do anything to prevent the onset of dementia or other forms of cognitive decline, clinicians can use the results of this review to inform the discussion.
-
There is some evidence that specific cognitive exercises can sharpen memory and have an incremental benefit in preventing cognitive decline. However, the transferability of these benefits to any cognitively stimulating activity is unproven.
-
There is some evidence that physical exercise may have a positive benefit, and given its countless other medical benefits, it should be encouraged with all patients.
-
Perhaps the most important application of this review can be the rebuttal of claims of many natural health food products and other pharmacologic agents that purport benefits to cognition.
-
For patients seeking further information and resources, clinicians may direct them to websites such as the following one created by the Alzheimer’s Association: www.alz.org/we_can_help_brain_health_maintain_your_brain.asp.
Conclusion
We found 32 RCTs of interventions
targeted to prevent cognitive decline in healthy older adults, but many
were small and had
short follow-up periods. None of the studies of
pharmacologic agents found clinically or statistically significant
benefits
associated with their use. More promising results
were seen in the studies that assessed cognitive training; all 3 RCTs
showed
some benefit in the prevention of cognitive decline
(Box 2).
However, the clinical significance of these results is not clear given
that the changes on the cognitive scales used as
outcomes in these studies were small. One of 3
studies assessing physical exercise, specifically resistance training,
showed
some potential benefit of physical training in
preventing cognitive decline in healthy older adults.
This review highlights that despite the importance of cognitive impairment, there is not a substantial body of literature
addressing how it may be prevented.
Key points-
There is no consistent evidence of benefit for any pharmacologic agent in preventing cognitive decline in healthy older adults.
-
Studies investigating estrogen therapies and anti-inflammatory medications have shown evidence of a decline in memory.
-
The evidence for physical activity in preventing cognitive decline is weak.
-
Formal cognitive training exercises may have a benefit in preventing cognitive decline.
Footnotes
-
Competing interests: None declared.
-
Disclaimer: Sharon Straus is an associate editor for CMAJ. She was not involved in the editorial decision-making process for this article.
-
This article has been peer reviewed.
-
Contributors: Raza Naqvi was involved in the literature search, abstract review, full-text review, data abstraction, manuscript drafting and editing. Dan Liberman was involved in the abstract review, full-text review, data abstraction and manuscript editing. Jarred Rosenberg and Jillian Alston were involved in the abstract review, data abstraction and manuscript editing. Sharon Straus was involved in the conception and design of the study and manuscript editing. All of the authors gave final approval of the version submitted for publication.
